Fig. 2: Survival outcomes. | Nature Cancer

Fig. 2: Survival outcomes.

From: Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial

Fig. 2

a, Kaplan–Meier curve of PFS at the first efficacy analysis in the full analysis set assessed by BIRC per RECIST (v.1.1). Number of participants: 281 and 140 in the suvemcitug and placebo arms, respectively. P < 0.0001. b, Kaplan–Meier curve of OS in the full analysis set at the final analysis. Number of participants: 281 and 140 in the suvemcitug and placebo arms, respectively. P = 0.03. PBO + CT, placebo plus chemotherapy; SV + CT, suvemcitug plus chemotherapy.

Source data

Back to article page